Skip to main content
SpringerLink
Log in

A novel approach to cancer therapy using PX-478 as a HIF-1α inhibitor

  • Report on Investigational Drugs
  • Published:
Archives of Pharmacal Research Aims and scope Submit manuscript

Abstract

Hypoxia-inducible factor-1α (HIF-1α) is a transcription factor produced by tumor cells under hypoxic conditions, and a key regulator of a number of genes important in cancer biology. Over-expression of HIF-1α in human tumors is associated with poor prognosis and poor therapeutic outcomes and HIF-1α has been suggested as a novel target for cancer therapy. This article provides a review of PX-478 as the first novel HIF-1α inhibitor in clinical stage for the treatment of solid tumors.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  • Aebersold, D. M., Burri, P., Beer, K. T., Laissue, J., Djonov, V., Greiner, R. H., and Semenza, G. L., Expression of hypoxiainducible factor-1α: a novel predictive and prognostic parameter in the radiotherapy of oropharyngeal cancer. Cancer Res., 61, 2911–2916 (2001).

    PubMed  CAS  Google Scholar 

  • Belozerov, V. E. and Van Meir, E. G., Hypoxia inducible factor-1: a novel target for cancer therapy. Anticancer Drugs, 16, 901–909 (2005).

    Article  PubMed  CAS  Google Scholar 

  • Koh, M. Y., Spivak-Kroizman, T., Venturini, S., Welsh, S., Williams, R. R., Kirkpatrick, D. L., and Powis, G., Molecular mechanisms for the activity of PX-478, an antitumor inhibitor of the hypoxia-inducible factor-1alpha. Mol. Cancer Ther., 7, 90–100 (2008).

    Article  PubMed  CAS  Google Scholar 

  • Kung, A. L., Wang, S., Klco, J. M., Kaelin, W. G., and Livingston, D. M., Suppression of tumor growth through disruption of hypoxia-inducible transcription. Nat. Med., 6, 1335–1340 (2000).

    Article  PubMed  CAS  Google Scholar 

  • Lee, J. W., Bae, S. H., Jeong, J. W., Kim, S. H., and Kim, K. W., Hypoxia-inducible factor (HIF-1)α: its protein stability and biological functions. Exp. Mol. Med., 36, 1–12 (2004).

    PubMed  Google Scholar 

  • Macpherson, G. R. and Figg, W. D., Small molecule-mediated anti-cancer therapy via hypoxia-inducible factor-1 blockade. Cancer Biol. Ther., 3, 503–504 (2004).

    PubMed  CAS  Google Scholar 

  • Onnis, B., Rapisarda, A., and Melillo, G., Development of HIF-1 inhibitors for cancer therapy. J. Cell. Mol. Med., 13, 2780–2786 (2009).

    Article  PubMed  CAS  Google Scholar 

  • Schwartz, D. L., Powis, G., Thitai-Kumar, A., He, Y., Bankson, J., Williams, R., Lemos, R., Oh, J., Volgin, A., Soghomonyan, S., Nishii, R., Alauddin, M., Mukhopadhay, U., Peng, Z., Bornmann, W., and Gelovani, J., The selective hypoxia inducible factor-1 inhibitor PX-478 provides in vivo radiosensitization through tumor stromal effects. Mol. Cancer Ther., 8, 947–958 (2009).

    Article  PubMed  CAS  Google Scholar 

  • Schwartz, D. L., Bankson, J. A., Lemos, R., Jr., Lai, S. Y., Thittai, A. K., He, Y., Hostetter, G., Demeure, M. J., Von Hoff, D. D., and Powis, G., Radiosensitization and stromal imaging response correlates for the HIF-1 inhibitor PX-478 given with or without chemotherapy in pancreatic cancer. Mol. Cancer Ther., 9, 2057–2067 (2010).

    Article  PubMed  CAS  Google Scholar 

  • Tibes, R., Falchook, G. S., Von Hoff, D. D., Weiss, G. J., Iyengar, T., Kurzrock, R., Pestano, L., Lowe, A. M., and Herbst, R. S., Results from a phase I, dose-escalation study of PX-478, an orally available inhibitor of HIF-1α. J. Clin. Oncol., 28, abstr 3076 (2010).

    Google Scholar 

  • Welsh, S., Williams, R., Kirkpatrick, L., Paine-Murrieta, G., and Powis, G., Antitumor activity and pharmacodynamic properties of PX-478, an inhibitor of hypoxia-inducible factor-1alpha. Mol. Cancer Ther., 3, 233–244 (2004).

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. College of Pharmacy, Dongguk University-Seoul, Seoul, 100-715, Korea

    Kyeong Lee

  2. College of Pharmacy, Gachon University of Medicine and Science, Incheon, 406-799, Korea

    Hwan Mook Kim

Authors
  1. Kyeong Lee
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Hwan Mook Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Hwan Mook Kim.

Additional information

Edited by Sang-Bae Han, College of Pharmacy, Chungbuk National University, Cheongju 361-763, Korea Tel: 82-43-261-2815 E-mail: shan@chungbuk.ac.kr

Hwan Mook Kim College of Pharmacy, Gachon University of Medicine and Science

Main Research Area

Cancer therapeutics: HIF-1, Runx-3, PRX, HDAC

Lead optimization: efficacy, PK, toxicity

Development of new methods of pharmacology

Rights and permissions

Reprints and permissions

About this article

Cite this article

Lee, K., Kim, H.M. A novel approach to cancer therapy using PX-478 as a HIF-1α inhibitor. Arch. Pharm. Res. 34, 1583–1585 (2011). https://doi.org/10.1007/s12272-011-1021-3

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12272-011-1021-3

Keywords

Search

Navigation